Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?

Carfilzomib (Cfz) has been associated with an ~5% incidence of unexplained and unpredictable cardiovascular toxicity in clinical trials. We therefore implemented a detailed, prospective, clinical cardiac and renal evaluation of 62 Cfz-treated myeloma patients, including serial blood pressure (BP), c...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenthal, A, Luthi, J, Belohlavek, M, Kortüm, K M, Mookadam, F, Mayo, A, Fonseca, R, Bergsagel, P L, Reeder, C B, Mikhael, J R, Stewart, A K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742629/
https://www.ncbi.nlm.nih.gov/pubmed/26771810
http://dx.doi.org/10.1038/bcj.2015.112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742629/
https://www.ncbi.nlm.nih.gov/pubmed/26771810
http://dx.doi.org/10.1038/bcj.2015.112

Ejemplares similares